Please use this identifier to cite or link to this item:
Full metadata record
|dc.contributor.author||Siriporn C. Chattipakorn||en_US|
|dc.description.abstract||© 2017 Elsevier Masson SAS The beneficial effects of Fibroblast Growth Factor 21 (FGF21) on metabolic function and neuroprotection have been shown in earlier research. We have previously shown that the Dipeptidyl Peptidase 4 inhibitor, vildagliptin, also led to improved insulin sensitivity and brain function in the obese-insulin resistant condition. However, the comparative efficacy on the improvement of metabolic function and neuroprotection between FGF21 and vildagliptin in the obese-insulin resistant condition has never been investigated. Twenty-four male Wistar rats were divided into two groups, and received either a normal diet (ND, n = 6) or a high fat diet (HFD, n = 18) for 16 weeks. At week 13, the HFD-fed rats were divided into three subgroups (n = 6/subgroup) to receive either a vehicle, recombinant human FGF21 (0.1 mg/kg/day) or vildagliptin (3 mg/kg/day), for four weeks. ND-fed rats were given a vehicle for four weeks. The metabolic parameters and brain function were subsequently investigated. The results demonstrated that the rats fed on HFD had obese-insulin resistance, increased systemic inflammation, brain mitochondrial dysfunction, increased brain apoptosis, impaired hippocampal plasticity, and demonstrated cognitive decline. FGF21 and vildagliptin effectively attenuated peripheral insulin resistance, brain mitochondrial dysfunction, brain apoptosis and cognitive decline. However, only FGF21 treatment led to significantly reduced body weight gain, visceral fat, systemic inflammation, improved hippocampal synaptic plasticity, enhanced FGF21 mediated signaling in the brain leading to prevention of early cognitive decline. These findings suggest that FGF21 exerts greater efficacy than vildagliptin in restoring metabolic function as well as brain function in cases of obese-insulin resistant rats.||en_US|
|dc.subject||Pharmacology, Toxicology and Pharmaceutics||en_US|
|dc.title||FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats||en_US|
|article.title.sourcetitle||Biomedicine and Pharmacotherapy||en_US|
|article.stream.affiliations||Chiang Mai University||en_US|
|article.stream.affiliations||Wenzhou Medical University||en_US|
|Appears in Collections:||CMUL: Journal Articles|
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.